Recurrence News - LARVOL Sigma

Recurrence

Welcome, Profile Billing Logout

121 Mechanisms of Action

«1 2...5 6 7 8 91011 12 13 14 15...16 17 »

|||||||||| Trial primary completion date: Moxonidine for Prevention of Post-ablation AFib Recurrences (clinicaltrials.gov) - May 3, 2014
P4, N=150, Completed, Sponsor: Spyridon Deftereos
Trial primary completion date: Dec 2013 --> Nov 2013

|||||||||| Trial initiation date: Moxonidine for Prevention of Post-ablation AFib Recurrences (clinicaltrials.gov) - May 3, 2014
P4, N=150, Completed, Sponsor: Spyridon Deftereos
Trial primary completion date: Dec 2013 --> Nov 2013 Initiation date: Sep 2012 --> Aug 2012

|||||||||| Trial completion date: Moxonidine for Prevention of Post-ablation AFib Recurrences (clinicaltrials.gov) - May 3, 2014
P4, N=150, Completed, Sponsor: Spyridon Deftereos
Initiation date: Sep 2012 --> Aug 2012 Trial completion date: Mar 2014 --> Apr 2014

|||||||||| Trial completion: Moxonidine for Prevention of Post-ablation AFib Recurrences (clinicaltrials.gov) - May 3, 2014
P4, N=150, Completed, Sponsor: Spyridon Deftereos
Trial completion date: Mar 2014 --> Apr 2014 Recruiting --> Completed

|||||||||| Trial primary completion date: Lamotrigine Phase III Study in Bipolar I Disorder (clinicaltrials.gov) - Apr 30, 2014
P3, N=250, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Trial primary completion date: May 2016 --> Mar 2016

|||||||||| Trial completion date: Lamotrigine Phase III Study in Bipolar I Disorder (clinicaltrials.gov) - Apr 30, 2014
P3, N=250, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2016 --> Mar 2016 Trial completion date: May 2016 --> Mar 2016

|||||||||| Trial initiation date: Lamotrigine Phase III Study in Bipolar I Disorder (clinicaltrials.gov) - Apr 30, 2014
P3, N=250, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: May 2016 --> Mar 2016 Initiation date: May 2012 --> Aug 2012

|||||||||| Enrollment open: IGPC-3: Prospective Study Using Hybrid PET/MRI to Evaluate Men With Suspected Recurrence Following Treatment for Prostate Cancer (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=40, Recruiting, Sponsor: Lawson Health Research Institute
Initiation date: May 2012 --> Aug 2012 Not yet recruiting --> Recruiting

|||||||||| Clinical: Laparoscopic Incisional Hernia Repair in Liver Transplant Patients (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=112, Completed, Sponsor: Medical University Innsbruck

|||||||||| Enrollment change: Modified "Open Intraperitoneal Mesh" Technique of Incisional Ventral Hernia Repair (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=100, Recruiting, Sponsor: Varazdin General Hospital
Not yet recruiting --> Recruiting N=55 --> 100

|||||||||| Enrollment change: ABSTACK: Risk of Recurrence After Incisional Hernia Repair With Mesh Fixation With Absorbable Versus Non-absorbable Tacks (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=816, Completed, Sponsor: Hvidovre University Hospital
N=55 --> 100 N=1081 --> 816

|||||||||| Enrollment open: Modified "Open Intraperitoneal Mesh" Technique of Incisional Ventral Hernia Repair (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=100, Recruiting, Sponsor: Varazdin General Hospital
N=1081 --> 816 Completed --> Recruiting

|||||||||| Trial completion: ABSTACK: Risk of Recurrence After Incisional Hernia Repair With Mesh Fixation With Absorbable Versus Non-absorbable Tacks (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=816, Completed, Sponsor: Hvidovre University Hospital
Completed --> Recruiting Enrolling by invitation --> Completed

||||||||||  ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Trial initiation date:  Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) (clinicaltrials.gov) -  Apr 21, 2014
P3, N=125, Completed,  Sponsor: Merck Sharp & Dohme Corp.
Enrolling by invitation --> Completed Initiation date: Jun 2006 --> May 2006

|||||||||| Clinical: Modified Limberg Procedure Versus Lateral Advancement Flap With Burrow's Triangle Procedure in the Treatment of Pilonidal Sinus (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=1, Completed, Sponsor: Ankara Mevki Military Hospital

||||||||||  midazolam hydrochloride / Generic mfg.
New P3 trial:  2-octyl Cyanoacrylate for Closure of Urethrocutaneous Fistula. (clinicaltrials.gov) -  Apr 13, 2014
P3, N=42, Recruiting,  Sponsor: Instituto Mexicano del Seguro Social

||||||||||  Avastin (bevacizumab) / Roche
Trial completion:  Bevacizumab for Recurrent Malignant Glioma (clinicaltrials.gov) -  Apr 12, 2014
P2, N=88, Completed,  Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2006 --> May 2006 Active, not recruiting --> Completed

|||||||||| New P1/2 trial: Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients (clinicaltrials.gov) - Apr 9, 2014
P1/2, N=60, Recruiting, Sponsor: University of Lausanne Hospitals

|||||||||| Trial withdrawal: MR-Guided Laser Ablation of Prostate Bed Recurrences (clinicaltrials.gov) - Apr 8, 2014
P=N/A, N=0, Withdrawn, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Withdrawn

|||||||||| Enrollment change: MR-Guided Laser Ablation of Prostate Bed Recurrences (clinicaltrials.gov) - Apr 8, 2014
P=N/A, N=0, Withdrawn, Sponsor: Mayo Clinic
Recruiting --> Withdrawn N=19 --> 0

||||||||||  aspirin / Generic mfg., lansoprazole / Generic mfg.
Clinical:  Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin (clinicaltrials.gov) -  Mar 27, 2014
P=N/A, N=3366, Completed,  Sponsor: Takeda

||||||||||  lansoprazole / Generic mfg.
Clinical:  Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs (clinicaltrials.gov) -  Mar 27, 2014
P=N/A, N=3502, Active, not recruiting,  Sponsor: Takeda

|||||||||| Biomarker, Trial completion: Biomarkers In Seizure To Predict Recurrence and Severe Outcomes (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=300, Completed, Sponsor: Bistro Study Group
N=19 --> 0 Recruiting --> Completed

|||||||||| Trial completion: Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease (clinicaltrials.gov) - Mar 19, 2014
P=N/A, N=91, Completed, Sponsor: Jinling Hospital, China
Recruiting --> Completed Recruiting --> Completed

|||||||||| Clinical: CMMV: Assessing the Rates of Major Complications in Combined Mini-incision Microscopic Varicocelectomy (clinicaltrials.gov) - Mar 18, 2014
P=N/A, N=285, Completed, Sponsor: Omid Fertility Center

||||||||||  remifentanil / Generic mfg., sevoflurane / Generic mfg.
Clinical:  Comparison of the Effect of Total Intravenous Anesthesia and Inhalation Anesthesia on Cancer Cell Cytotoxicity, Micrometastasis and Recurrence of Tumor in Patients Undergoing Breast Tumor Resection (clinicaltrials.gov) -  Mar 13, 2014
P=N/A, N=200, Recruiting,  Sponsor: Yonsei University

|||||||||| Clinical: Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm) (clinicaltrials.gov) - Mar 13, 2014
P=N/A, N=400, Active, not recruiting, Sponsor: University Hospital Inselspital, Berne

|||||||||| Enrollment change: MyLIFE: My Lifestyle Intervention of Food and Exercise (clinicaltrials.gov) - Mar 12, 2014
P=N/A, N=120, Recruiting, Sponsor: University of Florida
Recruiting --> Completed N=220 --> 120

||||||||||  TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
New P3 trial:  Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma (clinicaltrials.gov) -  Mar 9, 2014
P3, N=168, Enrolling by invitation,  Sponsor: National Institute of Cancerolog

||||||||||  Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases:  Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy (clinicaltrials.gov) -  Mar 5, 2014
P2, N=25, Completed,  Sponsor: Austrian Breast & Colorectal Cancer Study Group
N=220 --> 120 Active, not recruiting --> Completed

||||||||||  candesartan cilexetil / Generic mfg.
Trial completion:  Candesartan in the Prevention of Relapsing Atrial Fibrillation (clinicaltrials.gov) -  Feb 22, 2014
P3, N=200, Completed,  Sponsor: Asker & Baerum Hospital
Active, not recruiting --> Completed No longer recruiting --> Completed

||||||||||  colchicine / Generic mfg.
Trial completion:  Study of Colchicine to Prevent the Postpericardiotomy Syndrome (clinicaltrials.gov) -  Feb 22, 2014
P3, N=360, Completed,  Sponsor: Azienda Sanitaria Locale 3, Torino
No longer recruiting --> Completed Recruiting --> Completed

||||||||||  colchicine / Generic mfg.
Trial completion:  CORP: Study of Colchicine to Treat and Prevent Recurrent Pericarditis (First Episode) (clinicaltrials.gov) -  Feb 22, 2014
P3, N=120, Completed,  Sponsor: Azienda Sanitaria Locale 3, Torino
Recruiting --> Completed Recruiting --> Completed

||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial completion:  1-Year Follow up to the 1473-IMIQ Study (clinicaltrials.gov) -  Feb 22, 2014
P3, N=84, Completed,  Sponsor: Graceway Pharmaceuticals, LLC
Recruiting --> Completed No longer recruiting --> Completed

||||||||||  simvastatin / Generic mfg.
Trial completion:  Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER) (clinicaltrials.gov) -  Feb 22, 2014
P2/3, N=500, Completed,  Sponsor: University of Calgary
No longer recruiting --> Completed Recruiting --> Completed

||||||||||  duloxetine / Generic mfg.
Trial completion:  Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder (clinicaltrials.gov) -  Feb 22, 2014
P3, N=514, Completed,  Sponsor: Eli Lilly and Company
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Pegasys (pegylated interferon α -2a) / Roche
Trial completion:  PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. (clinicaltrials.gov) -  Feb 22, 2014
P4, N=115, Completed,  Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  cintredekin besudotox (hIL13-PE38QQR) / Insys Therap
Trial completion:  The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) -  Feb 22, 2014
P3, N=300, Completed,  Sponsor: Insys Therapeutics Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial completion:  A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence (clinicaltrials.gov) -  Feb 22, 2014
P3, N=63, Completed,  Sponsor: Graceway Pharmaceuticals, LLC
Active, not recruiting --> Completed No longer recruiting --> Completed

||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
Trial completion, Metastases:  Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer (clinicaltrials.gov) -  Feb 22, 2014
P1, N=25, Completed,  Sponsor: Pharmacyclics
No longer recruiting --> Completed No longer recruiting --> Completed

||||||||||  Avastin (bevacizumab) / Roche
Trial completion, Combination therapy:  A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer) (clinicaltrials.gov) -  Feb 22, 2014
P2, N=122, Completed,  Sponsor: Genentech
No longer recruiting --> Completed No longer recruiting --> Completed

|||||||||| Trial completion, Metastases: Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy (clinicaltrials.gov) - Feb 22, 2014
P2, N=28, Completed, Sponsor: Pfizer
No longer recruiting --> Completed No longer recruiting --> Completed

||||||||||  pemetrexed / Generic mfg.
Trial completion:  Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix (clinicaltrials.gov) -  Feb 22, 2014
P2, N=0, Completed,  Sponsor: Gynecologic Oncology Group
No longer recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=99, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Recruiting --> Completed

|||||||||| Trial completion: Peptide Vaccination for Patients at High Risk for Recurrent Melanoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=138, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed

||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
Trial completion:  Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART) (clinicaltrials.gov) -  Feb 22, 2014
P3, N=550, Completed,  Sponsor: Pharmacyclics
No longer recruiting --> Completed No longer recruiting --> Completed

||||||||||  Oncophage (Heat Shock Protein Peptide Complex-96) / Agenus
Trial completion:  Survival Study Of Oncophage (clinicaltrials.gov) -  Feb 22, 2014
P3, N=650, Completed,  Sponsor: Agenus, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed

||||||||||  erlotinib / Generic mfg.
Trial completion:  Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix (clinicaltrials.gov) -  Feb 22, 2014
P2, N=51, Completed,  Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Suspended --> Completed

|||||||||| Trial completion: S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=322, Completed, Sponsor: Southwest Oncology Group
Suspended --> Completed Active, not recruiting --> Completed

||||||||||  ifosfamide / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases:  Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus (clinicaltrials.gov) -  Feb 19, 2014
P3, N=166, Completed,  Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed